Announcements Trials
Browse Landscape

Phase

Phase 2 93Phase 1 23Phase 1/2 13Phase 3 9Phase NA 3Phase EARLY_PHASE1 3Phase 4 3Phase 2/3 3

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × enzalutamide × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Zhongnan Hospital

Phase 2/3 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed
100 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡